🔴 Definium Therapeutics is trading 4.76% down with no clear company-specific catalyst identified

Definium Therapeutics is trading at $31.82, down 4.76%, with no clear company-specific catalyst identified.

• Definium announced poster presentations of its already-reported positive Phase 3 data at the NEI Fall Congress; the announcement does not establish a reason for the decline.
• Broader indexes and biotech are moving higher, which does not explain this opposite-direction move. The company’s Q3 2026 results call is scheduled for November 9.